The University of Chicago Header Logo

Connection

Peter H. O'Donnell to Androgen Receptor Antagonists

Back to Details
This is a "connection" page, showing publications Peter H. O'Donnell has written about Androgen Receptor Antagonists.
Peter H. O'Donnell
Connection Strength
0.059
Androgen Receptor Antagonists
  1. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.